The global nuclear medicine market is entering a period of sustained expansion, with the market valued at USD 24.1 billion in 2026, estimated to reach USD 25.41 billion in 2027, and projected to attain USD 45.07 billion by 2036, representing a 6.46% CAGR from 2027 to 2036. The underlying market opportunity is increasingly shaped by the convergence of diagnostic imaging, targeted radiopharmaceutical therapies, and precision oncology. Rather than treating imaging and therapy as separate clinical functions, the industry is moving toward integrated approaches in which molecular imaging can help identify suitable patients, guide treatment decisions, and monitor therapeutic response.

This transition is particularly significant as cancer incidence and the demand for more targeted treatment strategies increase. Theranostics is emerging as an important bridge between diagnosis and therapy because the same molecular target can support both patient identification and subsequent treatment planning. The growing clinical relevance of radiopharmaceutical-based approaches is encouraging pharmaceutical companies, technology providers, hospitals, and isotope suppliers to strengthen their positions across the broader nuclear medicine value chain.

Diagnostics remains a major contributor to market activity because nuclear imaging is routinely used for disease detection, staging, treatment planning, and monitoring. However, the increasing integration of targeted radiopharmaceutical therapies is expanding the commercial scope of the industry beyond conventional imaging. This creates opportunities for companies capable of combining radiopharmaceutical development, isotope access, imaging technologies, clinical infrastructure, and specialized treatment capabilities.

The market's evolution also has implications for healthcare providers. Hospitals increasingly need capabilities that support multidisciplinary oncology pathways, including imaging, radiopharmaceutical handling, treatment administration, and patient monitoring. Consequently, future competitive differentiation is likely to depend not only on individual products but also on the ability to deliver reliable and coordinated clinical solutions.

Regional Analysis: North America's Established Base Meets Asia Pacific's Expansion

North America currently occupies a leading position in the nuclear medicine market, supported by advanced healthcare infrastructure, established diagnostic and therapeutic procedures, and strong radioisotope supply and clinical networks. The region's mature hospital and specialty-center ecosystem provides a strong foundation for nuclear imaging and radiopharmaceutical adoption. Established clinical expertise also supports the introduction of more sophisticated applications, particularly in oncology and targeted therapies.

Asia Pacific presents a different market dynamic. The region is identified as a high-growth hub, with growth of 13.1% CAGR, driven by increasing healthcare investment, broader access to diagnostic imaging, and greater adoption of radiopharmaceutical therapies. The expansion of hospital infrastructure across developing healthcare systems is particularly relevant because nuclear medicine requires specialized imaging equipment, trained personnel, isotope logistics, and appropriate clinical facilities.

Regional market	Key characteristics	Strategic opportunity
North America	Mature healthcare infrastructure, established diagnostic and therapeutic procedures, strong isotope and clinical networks	Advanced theranostics, targeted oncology, specialized clinical applications
Asia Pacific	Rising healthcare investment, improving imaging access, expanding adoption of radiopharmaceutical therapies	Infrastructure expansion, imaging access, radiopharmaceutical deployment

The contrast between the two regions creates different strategic priorities for market participants. In North America, opportunities are increasingly associated with technology advancement, clinical specialization, and the expansion of targeted applications. In Asia Pacific, market development is more closely connected with healthcare-capacity expansion and improved access to nuclear medicine.

For suppliers, this distinction matters. Established markets can support sophisticated products and integrated solutions, while high-growth markets may create demand for infrastructure, equipment, radiopharmaceutical supply, and clinical capabilities. Companies that understand these different adoption conditions can align their commercial strategies with regional healthcare development rather than applying a uniform market approach.

Industry Challenge: Supply Reliability and Specialized Infrastructure Remain Critical

One of the central challenges for nuclear medicine is that clinical adoption depends on more than demand for diagnostic or therapeutic procedures. The industry requires a coordinated ecosystem involving radioisotope availability, radiopharmaceutical production, specialized equipment, qualified personnel, regulatory compliance, and healthcare facilities capable of administering nuclear medicine procedures.

Supply-chain resilience is therefore becoming an increasingly important commercial consideration. The development of radiopharmaceutical therapies can create substantial clinical opportunities, but those opportunities depend on reliable access to the required isotopes and the infrastructure needed to process and administer them. Any disruption in the supply chain can affect treatment scheduling, imaging availability, and the ability of healthcare providers to maintain consistent clinical services.

Infrastructure availability is another constraint, particularly as adoption expands into markets where nuclear medicine capabilities are still developing. Hospitals need specialized imaging systems, radiopharmaceutical management capabilities, appropriate treatment environments, and trained clinical teams. Expansion of these capabilities can require significant institutional investment and coordination.

The challenge also extends to the integration of diagnostic and therapeutic workflows. As theranostics becomes more prominent, healthcare organizations may need to connect imaging departments, nuclear medicine teams, oncology specialists, pharmacy functions, and patient-monitoring services more closely.

Recent industry activity illustrates the strategic importance of this issue. SHINE Technologies' funding initiative is directed toward expanding radioisotope production capacity and addressing supply-chain vulnerabilities associated with SPECT imaging agents. Such investments indicate that market growth is increasingly tied to strengthening the underlying supply infrastructure rather than simply developing new clinical applications.

For industry participants, this creates an important strategic distinction: innovation in nuclear medicine must be supported by dependable production, distribution, and clinical delivery systems. Companies able to address these operational requirements can contribute to reducing bottlenecks that otherwise limit the wider adoption of nuclear medicine technologies.

Product and Segment Comparison: Diagnostics and Therapeutics Expand the Nuclear Medicine Opportunity

Diagnostics and therapeutics represent two increasingly interconnected components of the nuclear medicine industry. Diagnostics held a 73.49% market share in 2026, reflecting the widespread use of nuclear imaging for disease detection, staging, treatment planning, and monitoring. Therapeutics, meanwhile, represents an important area of emerging opportunity as targeted radiopharmaceutical treatments gain greater relevance in precision oncology.

Diagnostics

Diagnostic applications primarily support the identification and characterization of disease. Nuclear imaging can provide functional and molecular information that complements conventional imaging approaches. Its role across detection, staging, and treatment monitoring gives diagnostic nuclear medicine a broad presence within clinical workflows.

The established nature of diagnostic applications also supports demand for imaging equipment, radioisotopes, radiopharmaceutical agents, and related clinical services. Hospitals and specialty centers require these capabilities as part of routine diagnostic pathways.

Therapeutics

Therapeutic applications use radiopharmaceuticals to deliver radiation more selectively to disease-associated targets. This approach is particularly relevant to oncology because treatment can potentially be directed toward specific biological characteristics identified through molecular imaging.

The growing emphasis on theranostics strengthens the relationship between the two segments. Diagnostic imaging can help identify appropriate molecular targets, while therapeutic radiopharmaceuticals can subsequently address those targets. This creates a more integrated clinical model in which imaging and treatment contribute to a connected patient pathway.

For market participants, the comparison highlights two complementary opportunities. Diagnostics provides an established foundation supported by broad clinical utilization, while therapeutics offers an avenue for expanding the role of nuclear medicine into targeted treatment. Companies operating across both areas can potentially participate in a wider portion of the clinical value chain.

Geographic Opportunity: Four Markets With Distinct Nuclear Medicine Potential

The nuclear medicine market offers opportunities across both established healthcare systems and rapidly developing markets. Four geographic markets are particularly relevant from a strategic perspective:

• United States: The country's advanced healthcare infrastructure, established diagnostic and therapeutic procedures, and strong clinical networks create a favorable environment for sophisticated nuclear medicine applications. The market is particularly relevant for targeted oncology, theranostics, and advanced radiopharmaceutical development.
• Canada: Canada forms part of the established North American nuclear medicine ecosystem, with access to developed healthcare infrastructure and clinical capabilities. Its strategic relevance includes specialized diagnostic and therapeutic applications and participation in the broader regional radiopharmaceutical network.
• China: China's expanding healthcare investment and growing access to diagnostic technologies position it as an important market within the Asia Pacific opportunity. Expansion of healthcare capacity can support broader deployment of nuclear imaging and radiopharmaceutical-based approaches.
• India: India's expanding healthcare system and increasing demand for advanced diagnostic and therapeutic services create opportunities for nuclear medicine adoption. Growth in hospital capabilities and access to specialized imaging can support wider utilization of nuclear medicine technologies.

The strategic opportunity differs across these markets. North American markets provide an environment in which advanced applications can build on established infrastructure, while Asian markets offer opportunities associated with expanding healthcare access and clinical capacity. For equipment manufacturers, radiopharmaceutical developers, isotope suppliers, and healthcare providers, country-level strategies therefore need to account for differences in infrastructure maturity and clinical adoption.

Competitive Landscape: Companies Are Expanding Across Radiopharmaceuticals, Imaging, and Clinical Infrastructure

Competition in nuclear medicine is increasingly extending beyond individual diagnostic products. Companies are positioning themselves across radiopharmaceutical development, radioisotope production, imaging technology, clinical applications, and strategic partnerships. This reflects the industry's movement toward more integrated nuclear medicine and theranostic ecosystems.

Key market participants include GE HealthCare Technologies Inc., Cardinal Health, Inc., Lantheus Holdings, Inc., Bracco Imaging S.p.A., Mallinckrodt plc, Eckert & Ziegler SE, Nordion Inc., Curium Pharma, Jubilant Pharma Limited, and Eczacıbaşı-Monrol Nuclear Products Co.

Recent corporate activity demonstrates several strategic themes:

• Lantheus Holdings has strengthened its oncology positioning through partnerships focused on targeted radiopharmaceutical opportunities, illustrating the importance of pipeline development and external collaboration.
• Bracco Imaging and other imaging-focused participants represent the continuing importance of diagnostic technologies within the nuclear medicine ecosystem.
• Eckert & Ziegler and isotope-oriented companies highlight the critical role of radioisotope and radiopharmaceutical infrastructure in supporting downstream clinical applications.
• SHINE Technologies is expanding radioisotope production capacity, emphasizing supply security as a competitive factor.
• Catalyst MedTech has expanded its nuclear medicine imaging footprint through an acquisition, demonstrating how portfolio expansion can be used to strengthen capabilities in specialized imaging.

The competitive direction suggests that market positioning is increasingly influenced by ecosystem depth. Companies that can participate in multiple stages—from isotope supply and radiopharmaceutical development through imaging and clinical delivery—can address more of the operational requirements associated with nuclear medicine expansion. Partnerships, acquisitions, funding, and pipeline agreements are consequently becoming important mechanisms for building market capabilities.

Recent Industry News: Strategic Deals and Capacity Investments Reshape Nuclear Medicine

Recent developments across the nuclear medicine industry highlight a combination of pharmaceutical expansion, isotope-supply investment, strategic partnerships, and imaging consolidation.

December 2023 – Bristol Myers Squibb: Bristol Myers Squibb entered into a definitive agreement to acquire RayzeBio for $4.1 billion, expanding its oncology portfolio. The transaction included RayzeBio's peptide-based radiopharmaceutical programs and lutetium-177-related clinical development, reinforcing the growing pharmaceutical-industry interest in targeted radiopharmaceutical oncology.

January 2024 – Lantheus Holdings: Lantheus Holdings entered strategic agreements with Perspective Therapeutics involving an upfront $28 million cash payment. The agreement provided an exclusive option related to a lead-212-labeled alpha-radiopharmaceutical therapy for neuroendocrine tumors and established co-development rights for early-stage prostate cancer treatments. The development illustrates how licensing and co-development arrangements are being used to strengthen radiopharmaceutical pipelines.

October 2024 – Sanofi: Sanofi and Orano Med formed a strategic agreement to establish a new entity operating under the Orano Med brand. The venture focuses on the discovery, design, and clinical commercialization of next-generation radioligand therapies using alpha-emitting isotopes to address cancer.

March 2026 – SHINE Technologies: SHINE Technologies secured $240 million in funding led by NantWorks to accelerate development of its nuclear medicine division. The investment is intended to expand manufacturing infrastructure and production capacity for critical medical isotopes, including those used in SPECT imaging agents. The development underscores the importance of strengthening supply reliability as nuclear medicine adoption expands.

April 2026 – Catalyst MedTech: Catalyst MedTech completed the acquisition of X3D to scale its original equipment manufacturer platform and increase its presence in nuclear medicine imaging. The transaction integrates specialized radiological imaging technologies into Catalyst's portfolio, with a focus on diagnostic workflow and clinical software compatibility.

Taken together, these developments indicate that nuclear medicine competition is increasingly being shaped by oncology pipeline expansion, isotope supply security, strategic licensing, manufacturing investment, and imaging-platform consolidation. The direction of recent activity also demonstrates that growth opportunities are being pursued across both the therapeutic and diagnostic sides of the market, creating a broader and more interconnected competitive environment.

Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/nuclear-medicine-market-3318

About Fundamental Business Insights:

Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.

Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email:  sales@fundamentalbusinessinsights.com

Read This Report in Regional Languages - 

https://www.fundamentalbusinessinsights.com/ko/industry-report/nuclear-medicine-market-3318

https://www.fundamentalbusinessinsights.com/ja/industry-report/nuclear-medicine-market-3318

https://www.fundamentalbusinessinsights.com/de/industry-report/nuclear-medicine-market-3318

https://www.fundamentalbusinessinsights.com/it/industry-report/nuclear-medicine-market-3318

https://www.fundamentalbusinessinsights.com/es/industry-report/nuclear-medicine-market-3318          

https://www.fundamentalbusinessinsights.com/fr/industry-report/nuclear-medicine-market-3318